Download PDF
Semin Thromb Hemost 2011; 37(8): 961-978
DOI: 10.1055/s-0031-1297375
© Thieme Medical Publishers

Microvascular Thrombosis: A Serious and Deadly Pathologic Process in Multiple Diseases

Hau C. Kwaan1
  • 1Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
Further Information

Publication History

Publication Date:
23 December 2011 (online)

    Permissions and Reprints

ABSTRACT

Much of our understanding of the pathogenesis of thrombosis has long been based on observations made on large blood vessels. Nevertheless, there has been a recent shift in our attention to the microvasculature and to how microcirculatory occlusion affects function of various organs in diseases. This article provides an overview of microthrombosis in small blood vessels, with discussion of the progressive stages of its development. The initial event is triggered by a variety of diseases, followed by a second phase when multiple contributory factors amplify the process with the final phase of microvascular occlusion and microvascular thrombosis. The outcome is either recovery or injury to the affected organ. If the process is generalized, it is often associated with catastrophic or fatal outcomes. Our current knowledge of the major role of contributory factors leads to a new paradigm. A therapeutic approach limited to a single target of the underlying pathogenic factor, such as the use of anticoagulants, is insufficient and too often unsuccessful. Simultaneous management of all the contributory factors should therefore be considered.

KEYWORDS

Thrombosis - disseminated intravascular coagulation - inflammation - hypercoagulable state - sepsis

REFERENCES

  • 1 Aird W C. Spatial and temporal dynamics of the endothelium.  J Thromb Haemost. 2005;  3 (7) 1392-1406
    Google Scholar
  • 2 Lipowsky H H. Microvascular rheology and hemodynamics.  Microcirculation. 2005;  12 (1) 5-15
    Google Scholar
  • 3 Baskurt O K, Meiselman H J. Blood rheology and hemodynamics.  Semin Thromb Hemost. 2003;  29 (5) 435-450
    Google Scholar
  • 4 Aird W C. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms.  Circ Res. 2007;  100 (2) 158-173
    Google Scholar
  • 5 Aird W C. Phenotypic heterogeneity of the endothelium: II. Representative vascular beds.  Circ Res. 2007;  100 (2) 174-190
    Google Scholar
  • 6 Pries A R, Kuebler W M. Normal endothelium.  Handb Exp Pharmacol. 2006;  176 (176 Pt 1) 1-40
    Google Scholar
  • 7 Kwaan H C, Samama M M. The significance of endothelial heterogeneity in thrombosis and hemostasis.  Semin Thromb Hemost. 2010;  36 (3) 286-300
    Google Scholar
  • 8 Ishii H, Salem H H, Bell C E, Laposata E A, Majerus P W. Thrombomodulin, an endothelial anticoagulant protein, is absent from the human brain.  Blood. 1986;  67 (2) 362-365
    Google Scholar
  • 9 Esmon C T, Gu J M, Xu J, Qu D, Stearns-Kurosawa D J, Kurosawa S. Regulation and functions of the protein C anticoagulant pathway.  Haematologica. 1999;  84 (4) 363-368
    Google Scholar
  • 10 Lippi G, Franchini M. Pathogenesis of venous thromboembolism: when the cup runneth over.  Semin Thromb Hemost. 2008;  34 (8) 747-761
    Google Scholar
  • 11 Lippi G, Franchini M, Favaloro E J. Unsuspected triggers of venous thromboembolism—trivial or not so trivial?.  Semin Thromb Hemost. 2009;  35 (7) 597-604
    Google Scholar
  • 12 Virchow R. Phlogose und Thrombose in Gefabsystem. In: Gesammelte Abhandlungen zur Wissenschaftlichen Medizin. Frankfurt, Germany: Von Meidinger Sohn; 1856: 458
    Google Scholar
  • 13 Levi M, Schultz M, van der Poll T. Disseminated intravascular coagulation in infectious disease.  Semin Thromb Hemost. 2010;  36 (4) 367-377
    Google Scholar
  • 14 Galindo M, Gonzalo E, Martinez-Vidal M P et al.. Immunohistochemical detection of intravascular platelet microthrombi in patients with lupus nephritis and anti-phospholipid antibodies.  Rheumatology (Oxford). 2009;  48 (8) 1003-1007
    Google Scholar
  • 15 Nagy J A, Chang S H, Shih S C, Dvorak A M, Dvorak H F. Heterogeneity of the tumor vasculature.  Semin Thromb Hemost. 2010;  36 (3) 321-331
    Google Scholar
  • 16 Rubin D B, Drab E A, Ward W F. Physiological and biochemical markers of the endothelial cell response to irradiation.  Int J Radiat Biol. 1991;  60 (1-2) 29-32
    Google Scholar
  • 17 Kloner R A, Ganote C E, Jennings R B. The “no-reflow” phenomenon after temporary coronary occlusion in the dog.  J Clin Invest. 1974;  54 (6) 1496-1508
    Google Scholar
  • 18 Brands M T, van den Bosch S C, Dieleman F J, Bergé S J, Merkx M A. Prevention of thrombosis after microvascular tissue transfer in the head and neck. A review of the literature and the state of affairs in Dutch Head and Neck Cancer Centers.  Int J Oral Maxillofac Surg. 2010;  39 (2) 101-106
    Google Scholar
  • 19 Lecoq J P, Senard M, Hartstein G M, Lamy M, Heymans O. Thromboprophylaxis in microsurgery.  Acta Chir Belg. 2006;  106 (2) 158-164
    Google Scholar
  • 20 Kwaan H C, Bongu A. The hyperviscosity syndromes.  Semin Thromb Hemost. 1999;  25 (2) 199-208
    Google Scholar
  • 21 Esmon C T. The impact of the inflammatory response on coagulation.  Thromb Res. 2004;  114 (5-6) 321-327
    Google Scholar
  • 22 Esmon C T. The interactions between inflammation and coagulation.  Br J Haematol. 2005;  131 (4) 417-430
    Google Scholar
  • 23 Levi M. The coagulant response in sepsis and inflammation.  Hamostaseologie. 2010;  30 (1) 10-12, 14–16
    Google Scholar
  • 24 Bevilacqua M P, Pober J S, Majeau G R, Fiers W, Cotran R S, Gimbrone Jr M A. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1.  Proc Natl Acad Sci U S A. 1986;  83 (12) 4533-4537
    Google Scholar
  • 25 Coughlin S R. Thrombin signalling and protease-activated receptors.  Nature. 2000;  407 (6801) 258-264
    Google Scholar
  • 26 Bevilacqua M P, Nelson R M. Endothelial-leukocyte adhesion molecules in inflammation and metastasis.  Thromb Haemost. 1993;  70 (1) 152-154
    Google Scholar
  • 27 Gando S. Microvascular thrombosis and multiple organ dysfunction syndrome.  Crit Care Med. 2010;  38 (2, Suppl) S35-S42
    Google Scholar
  • 28 Lee C C, Marill K A, Carter W A, Crupi R S. A current concept of trauma-induced multiorgan failure.  Ann Emerg Med. 2001;  38 (2) 170-176
    Google Scholar
  • 29 Hertig A, Rondeau E. Role of the coagulation/fibrinolysis system in fibrin-associated glomerular injury.  J Am Soc Nephrol. 2004;  15 (4) 844-853
    Google Scholar
  • 30 Welty-Wolf K E, Carraway M S, Ortel T L, Piantadosi C A. Coagulation and inflammation in acute lung injury.  Thromb Haemost. 2002;  88 (1) 17-25
    Google Scholar
  • 31 Dhainaut J F, Marin N, Mignon A, Vinsonneau C. Hepatic response to sepsis: interaction between coagulation and inflammatory processes.  Crit Care Med. 2001;  29 (7, Suppl) S42-S47
    Google Scholar
  • 32 Papadopoulos M C, Davies D C, Moss R F, Tighe D, Bennett E D. Pathophysiology of septic encephalopathy: a review.  Crit Care Med. 2000;  28 (8) 3019-3024
    Google Scholar
  • 33 Stegmayr B G. Apheresis as therapy for patients with severe sepsis and multiorgan dysfunction syndrome.  Ther Apher. 2001;  5 (2) 123-127
    Google Scholar
  • 34 Levi M, Ten Cate H. Disseminated intravascular coagulation.  N Engl J Med. 1999;  341 (8) 586-592
    Google Scholar
  • 35 ten Cate H, Timmerman J J, Levi M. The pathophysiology of disseminated intravascular coagulation.  Thromb Haemost. 1999;  82 (2) 713-717
    Google Scholar
  • 36 Lippi G, Cervellin G. Disseminated intravascular coagulation in trauma injuries.  Semin Thromb Hemost. 2010;  36 (4) 378-387
    Google Scholar
  • 37 Kojima M, Shimamura K, Mori N, Oka K, Nakazawa M. A histological study on microthrombi in autopsy cases of DIC.  Bibl Haematol. 1983;  (49) 95-106
    Google Scholar
  • 38 Shimamura K, Oka K, Nakazawa M, Kojima M. Distribution patterns of microthrombi in disseminated intravascular coagulation.  Arch Pathol Lab Med. 1983;  107 (10) 543-547
    Google Scholar
  • 39 Schouten M, Wiersinga W J, Levi M, van der Poll T. Inflammation, endothelium, and coagulation in sepsis.  J Leukoc Biol. 2008;  83 (3) 536-545
    Google Scholar
  • 40 Osterud B. Tissue factor expression by monocytes: regulation and pathophysiological roles.  Blood Coagul Fibrinolysis. 1998;  9 (Suppl 1) S9-S14
    Google Scholar
  • 41 Meziani F, Delabranche X, Asfar P, Toti F. Bench-to-bedside review: circulating microparticles—a new player in sepsis?.  Crit Care. 2010;  14 (5) 236
    Google Scholar
  • 42 Soriano A O, Jy W, Chirinos J A et al.. Levels of endothelial and platelet microparticles and their interactions with leukocytes negatively correlate with organ dysfunction and predict mortality in severe sepsis.  Crit Care Med. 2005;  33 (11) 2540-2546
    Google Scholar
  • 43 McEver R P. GMP-140: a receptor for neutrophils and monocytes on activated platelets and endothelium.  J Cell Biochem. 1991;  45 (2) 156-161
    Google Scholar
  • 44 Klintman D, Li X, Thorlacius H. Important role of P-selectin for leukocyte recruitment, hepatocellular injury, and apoptosis in endotoxemic mice.  Clin Diagn Lab Immunol. 2004;  11 (1) 56-62
    Google Scholar
  • 45 Ward P A. Role of the complement in experimental sepsis.  J Leukoc Biol. 2008;  83 (3) 467-470
    Google Scholar
  • 46 Laudes I J, Chu J C, Huber-Lang M et al.. Expression and function of C5a receptor in mouse microvascular endothelial cells.  J Immunol. 2002;  169 (10) 5962-5970
    Google Scholar
  • 47 Esmon C T, Fukudome K, Mather T et al.. Inflammation, sepsis, and coagulation.  Haematologica. 1999;  84 (3) 254-259
    Google Scholar
  • 48 Levi M, Lowenberg E, Meijers J C. Recombinant anticoagulant factors for adjunctive treatment of sepsis.  Semin Thromb Hemost. 2010;  36 (5) 550-557
    Google Scholar
  • 49 Bernard G R, Vincent J L, Laterre P F Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group et al. Efficacy and safety of recombinant human activated protein C for severe sepsis.  N Engl J Med. 2001;  344 (10) 699-709
    Google Scholar
  • 50 Ely E W, Laterre P F, Angus D C PROWESS Investigators et al. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.  Crit Care Med. 2003;  31 (1) 12-19
    Google Scholar
  • 51 Dhainaut J F, Yan S B, Joyce D E et al.. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation.  J Thromb Haemost. 2004;  2 (11) 1924-1933
    Google Scholar
  • 52 Abraham E, Laterre P F, Garg R Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.  N Engl J Med. 2005;  353 (13) 1332-1341
    Google Scholar
  • 53 Levi M, Levy M, Williams M D Xigris and Prophylactic HepaRin Evaluation in Severe Sepsis (XPRESS) Study Group et al. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated).  Am J Respir Crit Care Med. 2007;  176 (5) 483-490
    Google Scholar
  • 54 Costa V, Brophy J M. Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis.  BMC Anesthesiol. 2007;  7 5
    Google Scholar
  • 55 Barie P S. “All in” for a huge pot: the PROWESS-SHOCK trial for refractory septic shock.  Surg Infect (Larchmt). 2007;  8 (5) 491-494
    Google Scholar
  • 56 Barie P S. Current role of activated protein C therapy for severe sepsis and septic shock.  Curr Infect Dis Rep. 2008;  10 (5) 368-376
    Google Scholar
  • 57 Bernard G R, Margolis B D, Shanies H M Extended Evaluation of Recombinant Human Activated Protein C United States Investigators et al. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.  Chest. 2004;  125 (6) 2206-2216
    Google Scholar
  • 58 Leitner J M, Firbas C, Mayr F B, Reiter R A, Steinlechner B, Jilma B. Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia.  Clin Pharmacol Ther. 2006;  79 (1) 23-34
    Google Scholar
  • 59 Warren B L, Eid A, Singer P KyberSept Trial Study Group et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.  JAMA. 2001;  286 (15) 1869-1878
    Google Scholar
  • 60 Ott I, Miyagi Y, Miyazaki K et al.. Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor.  Arterioscler Thromb Vasc Biol. 2000;  20 (3) 874-882
    Google Scholar
  • 61 Brandtzaeg P, Sandset P M, Joø G B, Ovstebø R, Abildgaard U, Kierulf P. The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease.  Thromb Res. 1989;  55 (4) 459-470
    Google Scholar
  • 62 Abraham E, Reinhart K, Opal S OPTIMIST Trial Study Group et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.  JAMA. 2003;  290 (2) 238-247
    Google Scholar
  • 63 van der Poll T, Levi M, Büller H R et al.. Fibrinolytic response to tumor necrosis factor in healthy subjects.  J Exp Med. 1991;  174 (3) 729-732
    Google Scholar
  • 64 Carmeliet P, Schoonjans L, Kieckens L et al.. Physiological consequences of loss of plasminogen activator gene function in mice.  Nature. 1994;  368 (6470) 419-424
    Google Scholar
  • 65 Bajzar L, Jain N, Wang P, Walker J B. Thrombin activatable fibrinolysis inhibitor: not just an inhibitor of fibrinolysis.  Crit Care Med. 2004;  32 (5, Suppl) S320-S324
    Google Scholar
  • 66 Leung L L, Nishimura T, Myles T. Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI).  Adv Exp Med Biol. 2008;  632 61-69
    Google Scholar
  • 67 Kwaan H C, Gordon L I. Thrombotic microangiopathy in the cancer patient.  Acta Haematol. 2001;  106 (1-2) 52-56
    Google Scholar
  • 68 Elliott M A, Letendre L, Gastineau D A, Winters J L, Pruthi R K, Heit J A. Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration.  Eur J Haematol. 2010;  85 (1) 43-50
    Google Scholar
  • 69 Zakarija A. Thrombotic microangiopathy syndromes.  Cancer Treat Res. 2009;  148 115-136
    Google Scholar
  • 70 Gordon L I, Kwaan H C. Cancer- and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.  Semin Hematol. 1997;  34 (2) 140-147
    Google Scholar
  • 71 Kwaan H C, Boggio L N. The clinical spectrum of thrombotic thrombocytopenic purpura.  Semin Thromb Hemost. 2005;  31 (6) 673-680
    Google Scholar
  • 72 Karpman D, Sartz L, Johnson S. Pathophysiology of typical hemolytic uremic syndrome.  Semin Thromb Hemost. 2010;  36 (6) 575-585
    Google Scholar
  • 73 Baronzio G, Freitas I, Kwaan H C. Tumor microenvironment and hemorheological abnormalities.  Semin Thromb Hemost. 2003;  29 (5) 489-497
    Google Scholar
  • 74 Brat D J, Van Meir E G. Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma.  Lab Invest. 2004;  84 (4) 397-405
    Google Scholar
  • 75 Wang J, Weiss I, Svoboda K, Kwaan H C. Thrombogenic role of cells undergoing apoptosis.  Br J Haematol. 2001;  115 (2) 382-391
    Google Scholar
  • 76 Rak J. Microparticles in cancer.  Semin Thromb Hemost. 2010;  36 (8) 888-906
    Google Scholar
  • 77 Kwaan H C, Rego E M. Role of microparticles in the hemostatic dysfunction in acute promyelocytic leukemia.  Semin Thromb Hemost. 2010;  36 (8) 917-924
    Google Scholar
  • 78 Key N S, Kwaan H C. Microparticles in thrombosis and hemostasis.  Semin Thromb Hemost. 2010;  36 (8) 805-806
    Google Scholar
  • 79 Myhre-Jensen O, Hansen E S, Butrago B. Renal microthrombosis. Incidence in 500 consecutive autopsies. Clinico-pathological relations.  Acta Pathol Microbiol Scand [A]. 1972;  80 (3) 403-411
    Google Scholar
  • 80 Shih H M, Lin C C, Shiao Y W. Pulmonary tumor thrombotic microangiopathy.  Am J Emerg Med. 2011;  29 (2) 241, e3-e4
    Google Scholar
  • 81 Chinen K, Tokuda Y, Fujiwara M, Fujioka Y. Pulmonary tumor thrombotic microangiopathy in patients with gastric carcinoma: an analysis of 6 autopsy cases and review of the literature.  Pathol Res Pract. 2010;  206 (10) 682-689
    Google Scholar
  • 82 Tehrani M, Friedman T M, Olson J J, Brat D J. Intravascular thrombosis in central nervous system malignancies: a potential role in astrocytoma progression to glioblastoma.  Brain Pathol. 2008;  18 (2) 164-171
    Google Scholar
  • 83 Hallahan D, Clark E T, Kuchibhotla J, Gewertz B L, Collins T. E-selectin gene induction by ionizing radiation is independent of cytokine induction.  Biochem Biophys Res Commun. 1995;  217 (3) 784-795
    Google Scholar
  • 84 Jahroudi N, Ardekani A M, Greenberger J S. Ionizing irradiation increases transcription of the von Willebrand factor gene in endothelial cells.  Blood. 1996;  88 (10) 3801-3814
    Google Scholar
  • 85 Verheij M, Dewit L G, van Mourik J A. The effect of ionizing radiation on endothelial tissue factor activity and its cellular localization.  Thromb Haemost. 1995;  73 (5) 894-895
    Google Scholar
  • 86 Hauer-Jensen M, Fink L M, Wang J. Radiation injury and the protein C pathway.  Crit Care Med. 2004;  32 (5, Suppl) S325-S330
    Google Scholar
  • 87 Astedt B, Bergentz S E, Svanberg L. Effect of irradiation on the plasminogen activator content in rat vessels.  Experientia. 1974;  30 (12) 1466-1467
    Google Scholar
  • 88 Dropcho E J. Neurotoxicity of radiation therapy.  Neurol Clin. 2010;  28 (1) 217-234
    Google Scholar
  • 89 Lyons A, Ghazali N. Osteoradionecrosis of the jaws: current understanding of its pathophysiology and treatment.  Br J Oral Maxillofac Surg. 2008;  46 (8) 653-660
    Google Scholar
  • 90 Madrid C, Abarca M, Bouferrache K. Osteoradionecrosis: an update.  Oral Oncol. 2010;  46 (6) 471-474
    Google Scholar
  • 91 Kwaan H C. Miscellaneous secondary thrombotic microangiopathy.  Semin Hematol. 1987;  24 (3) 141-147
    Google Scholar
  • 92 Kwaan H C. Thrombotic thrombocytopenic purpura: a diagnostic and therapeutic challenge.  Semin Thromb Hemost. 2005;  31 (6) 615-624
    Google Scholar
  • 93 Mitra D, Jaffe E A, Weksler B, Hajjar K A, Soderland C, Laurence J. Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells.  Blood. 1997;  89 (4) 1224-1234
    Google Scholar
  • 94 Laurence J, Mitra D. Apoptosis of microvascular endothelial cells in the pathophysiology of thrombotic thrombocytopenic purpura/sporadic hemolytic uremic syndrome.  Semin Hematol. 1997;  34 (2) 98-105
    Google Scholar
  • 95 Zipfel P F, Heinen S, Skerka C. Thrombotic microangiopathies: new insights and new challenges.  Curr Opin Nephrol Hypertens. 2010;  19 (4) 372-378
    Google Scholar
  • 96 Louise C B, Obrig T G. Shiga toxin-associated hemolytic-uremic syndrome: combined cytotoxic effects of Shiga toxin, interleukin-1 beta, and tumor necrosis factor alpha on human vascular endothelial cells in vitro.  Infect Immun. 1991;  59 (11) 4173-4179
    Google Scholar
  • 97 Louise C B, Obrig T G. Human renal microvascular endothelial cells as a potential target in the development of the hemolytic uremic syndrome as related to fibrinolysis factor expression, in vitro.  Microvasc Res. 1994;  47 (3) 377-387
    Google Scholar
  • 98 Dragon-Durey M A, Sethi S K, Bagga A et al.. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome.  J Am Soc Nephrol. 2010;  21 (12) 2180-2187
    Google Scholar
  • 99 Le Quintrec M, Roumenina L, Noris M, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome associated with mutations in complement regulator genes.  Semin Thromb Hemost. 2010;  36 (6) 641-652
    Google Scholar
  • 100 Heinen S, Hartmann A, Lauer N et al.. Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation.  Blood. 2009;  114 (12) 2439-2447
    Google Scholar
  • 101 Kwaan H C. Miscellaneous secondary thrombotic microangiopathy.  Semin Hematol. 1987;  24 (3) 141-147
    Google Scholar
  • 102 Kelton J G, Warkentin T E. Heparin-induced thrombocytopenia: a historical perspective.  Blood. 2008;  112 (7) 2607-2616
    Google Scholar
  • 103 Kwaan H C, Sakurai S. Endothelial cell hyperplasia contributes to thrombosis in heparin-induced thrombocytopenia.  Semin Thromb Hemost. 1999;  25 (Suppl 1) 23-27
    Google Scholar
  • 104 Baskurt O K, Meiselman H J. Blood rheology and hemodynamics.  Semin Thromb Hemost. 2003;  29 (5) 435-450
    Google Scholar
  • 105 Kwaan H C, Wang J. Hyperviscosity in polycythemia vera and other red cell abnormalities.  Semin Thromb Hemost. 2003;  29 (5) 451-458
    Google Scholar
  • 106 Newton C R, Marsh K, Peshu N, Kirkham F J. Perturbations of cerebral hemodynamics in Kenyans with cerebral malaria.  Pediatr Neurol. 1996;  15 (1) 41-49
    Google Scholar
  • 107 Beare N A, Harding S P, Taylor T E, Lewallen S, Molyneux M E. Perfusion abnormalities in children with cerebral malaria and malarial retinopathy.  J Infect Dis. 2009;  199 (2) 263-271
    Google Scholar
  • 108 Buffet P A, Safeukui I, Deplaine G et al.. The pathogenesis of Plasmodium falciparum malaria in humans: insights from splenic physiology.  Blood. 2011;  117 (2) 381-392
    Google Scholar
  • 109 Grau G E, Mackenzie C D, Carr R A et al.. Platelet accumulation in brain microvessels in fatal pediatric cerebral malaria.  J Infect Dis. 2003;  187 (3) 461-466
    Google Scholar
  • 110 Cox D, McConkey S. The role of platelets in the pathogenesis of cerebral malaria.  Cell Mol Life Sci. 2010;  67 (4) 557-568
    Google Scholar
  • 111 Baruch D I, Gormely J A, Ma C, Howard R J, Pasloske B L. Plasmodium falciparum erythrocyte membrane protein 1 is a parasitized erythrocyte receptor for adherence to CD36, thrombospondin, and intercellular adhesion molecule 1.  Proc Natl Acad Sci U S A. 1996;  93 (8) 3497-3502
    Google Scholar
  • 112 Chakravorty S J, Hughes K R, Craig A G. Host response to cytoadherence in Plasmodium falciparum.  Biochem Soc Trans. 2008;  36 (Pt 2) 221-228
    Google Scholar
  • 113 García F, Cebrián M, Dgedge M et al.. Endothelial cell activation in muscle biopsy samples is related to clinical severity in human cerebral malaria.  J Infect Dis. 1999;  179 (2) 475-483
    Google Scholar
  • 114 Francischetti I M, Seydel K B, Monteiro R Q et al.. Plasmodium falciparum-infected erythrocytes induce tissue factor expression in endothelial cells and support the assembly of multimolecular coagulation complexes.  J Thromb Haemost. 2007;  5 (1) 155-165
    Google Scholar
  • 115 Francischetti I M, Seydel K B, Monteiro R Q. Blood coagulation, inflammation, and malaria.  Microcirculation. 2008;  15 (2) 81-107
    Google Scholar
  • 116 Combes V, Taylor T E, Juhan-Vague I et al.. Circulating endothelial microparticles in malawian children with severe falciparum malaria complicated with coma.  JAMA. 2004;  291 (21) 2542-2544
    Google Scholar
  • 117 Milner Jr D A. Rethinking cerebral malaria pathology.  Curr Opin Infect Dis. 2010;  23 (5) 456-463
    Google Scholar
  • 118 Kato G J, Hebbel R P, Steinberg M H, Gladwin M T. Vasculopathy in sickle cell disease: biology, pathophysiology, genetics, translational medicine, and new research directions.  Am J Hematol. 2009;  84 (9) 618-625
    Google Scholar
  • 119 Morris C R. Mechanisms of vasculopathy in sickle cell disease and thalassemia.  Hematology (Am Soc Hematol Educ Program). 2008;  177-185
    Google Scholar
  • 120 Morris C R, Kato G J, Poljakovic M et al.. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease.  JAMA. 2005;  294 (1) 81-90
    Google Scholar
  • 121 Francis Jr R B. Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion.  Blood Coagul Fibrinolysis. 1991;  2 (2) 341-353
    Google Scholar
  • 122 Peters M, Plaat B E, ten Cate H, Wolters H J, Weening R S, Brandjes D P. Enhanced thrombin generation in children with sickle cell disease.  Thromb Haemost. 1994;  71 (2) 169-172
    Google Scholar
  • 123 Key N S, Slungaard A, Dandelet L et al.. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease.  Blood. 1998;  91 (11) 4216-4223
    Google Scholar
  • 124 Kurantsin-Mills J, Ofosu F A, Safa T K, Siegel R S, Lessin L S. Plasma factor VII and thrombin-antithrombin III levels indicate increased tissue factor activity in sickle cell patients.  Br J Haematol. 1992;  81 (4) 539-544
    Google Scholar
  • 125 Nsiri B, Gritli N, Bayoudh F, Messaoud T, Fattoum S, Machghoul S. Abnormalities of coagulation and fibrinolysis in homozygous sickle cell disease.  Hematol Cell Ther. 1996;  38 (3) 279-284
    Google Scholar
  • 126 Kurantsin-Mills J, Ibe B O, Natta C L, Raj J U, Siegel R S, Lessin L S. Elevated urinary levels of thromboxane and prostacyclin metabolities in sickle cell disease reflects activated platelets in the circulation.  Br J Haematol. 1994;  87 (3) 580-585
    Google Scholar
  • 127 Ataga K I, Orringer E P. Hypercoagulability in sickle cell disease: a curious paradox.  Am J Med. 2003;  115 (9) 721-728
    Google Scholar
  • 128 Gladwin M T, Kato G J. Hemolysis-associated hypercoagulability in sickle cell disease: the plot (and blood) thickens!.  Haematologica. 2008;  93 (1) 1-3
    Google Scholar
  • 129 Gladwin M T, Vichinsky E. Pulmonary complications of sickle cell disease.  N Engl J Med. 2008;  359 (21) 2254-2265
    Google Scholar
  • 130 Bunn H F, Nathan D G, Dover G J et al.. Pulmonary hypertension and nitric oxide depletion in sickle cell disease.  Blood. 2010;  116 (5) 687-692
    Google Scholar
  • 131 Gordeuk V R, Campbell A, Rana S et al.. Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease.  Blood. 2009;  114 (21) 4639-4644
    Google Scholar
  • 132 Machado R F, Martyr S, Kato G J et al.. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension.  Br J Haematol. 2005;  130 (3) 445-453
    Google Scholar
  • 133 Rose V L, Kwaan H C. Anti-Pr cold hemagglutination associated with livedo reticularis.  Am J Hematol. 1985;  19 (4) 419-421
    Google Scholar
  • 134 Ruch J, McMahon B, Ramsey G, Kwaan H C. Catastrophic multiple organ ischemia due to an anti-Pr cold agglutinin developing in a patient with mixed cryoglobulinemia after treatment with rituximab.  Am J Hematol. 2009;  84 (2) 120-122
    Google Scholar
  • 135 Blum W, Porcu P. Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome.  Semin Thromb Hemost. 2007;  33 (4) 350-354
    Google Scholar
  • 136 Porcu P, Danielson C F, Orazi A, Heerema N A, Gabig T G, McCarthy L J. Therapeutic leukapheresis in hyperleucocytic leukaemias: lack of correlation between degree of cytoreduction and early mortality rate.  Br J Haematol. 1997;  98 (2) 433-436
    Google Scholar
  • 137 Vaughan W P, Kimball A W, Karp J E, Dragon L H, Burke P J. Factors affecting survival of patients with acute myelocytic leukemia presenting with high wbc counts.  Cancer Treat Rep. 1981;  65 (11-12) 1007-1013
    Google Scholar
  • 138 Creutzig U, Ritter J, Budde M, Sutor A, Schellong G. Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia. Associations with hyperleukocytosis and acute monocytic leukemia.  Cancer. 1987;  60 (12) 3071-3079
    Google Scholar
  • 139 Cuttner J, Conjalka M S, Reilly M et al.. Association of monocytic leukemia in patients with extreme leukocytosis.  Am J Med. 1980;  69 (4) 555-558
    Google Scholar
  • 140 Scott C S, Stark A N, Limbert H J, Master P S, Head C, Roberts B E. Diagnostic and prognostic factors in acute monocytic leukaemia: an analysis of 51 cases.  Br J Haematol. 1988;  69 (2) 247-252
    Google Scholar
  • 141 Biondi A, Cimino G, Pieters R, Pui C H. Biological and therapeutic aspects of infant leukemia.  Blood. 2000;  96 (1) 24-33
    Google Scholar
  • 142 Stucki A, Rivier A S, Gikic M, Monai N, Schapira M, Spertini O. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination.  Blood. 2001;  97 (7) 2121-2129
    Google Scholar
  • 143 An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators.  N Engl J Med. 1993;  329 (10) 673-682
    Google Scholar
  • 144 Beek A M, Nijveldt R, van Rossum A C. Intramyocardial hemorrhage and microvascular obstruction after primary percutaneous coronary intervention.  Int J Cardiovasc Imaging. 2010;  26 (1) 49-55
    Google Scholar
  • 145 Patel B, Fisher M. Therapeutic advances in myocardial microvascular resistance: unravelling the enigma.  Pharmacol Ther. 2010;  127 (2) 131-147
    Google Scholar
  • 146 Bhavsar J, Rosenson R S. Adenosine transport, erythrocyte deformability and microvascular dysfunction: an unrecognized potential role for dipyridamole therapy.  Clin Hemorheol Microcirc. 2010;  44 (3) 193-205
    Google Scholar
  • 147 Bekkers S C, Yazdani S K, Virmani R, Waltenberger J. Microvascular obstruction: underlying pathophysiology and clinical diagnosis.  J Am Coll Cardiol. 2010;  55 (16) 1649-1660
    Google Scholar
  • 148 Buja L M. Myocardial ischemia and reperfusion injury.  Cardiovasc Pathol. 2005;  14 (4) 170-175
    Google Scholar
  • 149 Khouri R K. Free flap surgery. The second decade.  Clin Plast Surg. 1992;  19 (4) 757-761
    Google Scholar
  • 150 Ashjian P, Chen C M, Pusic A, Disa J J, Cordeiro P G, Mehrara B J. The effect of postoperative anticoagulation on microvascular thrombosis.  Ann Plast Surg. 2007;  59 (1) 36-39, discussion 39–40
    Google Scholar
  • 151 Radomski M W, Palmer R M, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium.  Lancet. 1987;  2 (8567) 1057-1058
    Google Scholar
  • 152 Azizzadeh B, Buga G M, Berke G S, Larian B, Ignarro L J, Blackwell K E. Inhibitors of nitric oxide promote microvascular thrombosis.  Arch Facial Plast Surg. 2003;  5 (1) 31-35
    Google Scholar
  • 153 Miyakis S, Lockshin M D, Atsumi T et al.. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).  J Thromb Haemost. 2006;  4 (2) 295-306
    Google Scholar
  • 154 Cervera R, Piette J C, Font J Euro-Phospholipid Project Group et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.  Arthritis Rheum. 2002;  46 (4) 1019-1027
    Google Scholar
  • 155 Espinosa G, Cervera R. Antiphospholipid syndrome: frequency, main causes and risk factors of mortality.  Nat Rev Rheumatol. 2010;  6 (5) 296-300
    Google Scholar
  • 156 Mehdi A A, Salti I, Uthman I. Antiphospholipid syndrome: endocrinologic manifestations and organ involvement.  Semin Thromb Hemost. 2011;  37 (1) 49-57
    Google Scholar
  • 157 Cervera R, Asherton R A. Catastrophic antiphospholipid syndrome.  Pathophysiol Haemost Thromb. 2006;  35 (1-2) 181-186
    Google Scholar
  • 158 Asherson R A, Cervera R, Piette J C et al.. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients.  Medicine (Baltimore). 1998;  77 (3) 195-207
    Google Scholar
  • 159 Asherson R A, Cervera R, Piette J C et al.. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients.  Medicine (Baltimore). 2001;  80 (6) 355-377
    Google Scholar
  • 160 Cervera R, Khamashta M A, Shoenfeld Y Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies) et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients.  Ann Rheum Dis. 2009;  68 (9) 1428-1432
    Google Scholar
  • 161 Bucciarelli S, Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: treatment, prognosis, and the risk of relapse.  Clin Rev Allergy Immunol. 2009;  36 (2-3) 80-84
    Google Scholar
  • 162 Stein S C, Smith D H. Coagulopathy in traumatic brain injury.  Neurocrit Care. 2004;  1 (4) 479-488
    Google Scholar
  • 163 Astrup T. Assay and content of tissue thromboplastin in different organs.  Thromb Diath Haemorrh. 1965;  14 (3-4) 401-416
    Google Scholar
  • 164 Goodnight S H, Kenoyer G, Rapaport S I, Patch M J, Lee J A, Kurze T. Defibrination after brain-tissue destruction: A serious complication of head injury.  N Engl J Med. 1974;  290 (19) 1043-1047
    Google Scholar
  • 165 Jacoby R C, Owings J T, Holmes J, Battistella F D, Gosselin R C, Paglieroni T G. Platelet activation and function after trauma.  J Trauma. 2001;  51 (4) 639-647
    Google Scholar
  • 166 Nekludov M, Antovic J, Bredbacka S, Blombäck M. Coagulation abnormalities associated with severe isolated traumatic brain injury: cerebral arterio-venous differences in coagulation and inflammatory markers.  J Neurotrauma. 2007;  24 (1) 174-180
    Google Scholar
  • 167 Dietrich W D. Morphological manifestations of reperfusion injury in brain.  Ann N Y Acad Sci. 1994;  723 15-24
    Google Scholar
  • 168 Dietrich W D, Alonso O, Halley M. Early microvascular and neuronal consequences of traumatic brain injury: a light and electron microscopic study in rats.  J Neurotrauma. 1994;  11 (3) 289-301
    Google Scholar
  • 169 Maeda T, Katayama Y, Kawamata T, Aoyama N, Mori T. Hemodynamic depression and microthrombosis in the peripheral areas of cortical contusion in the rat: role of platelet activating factor.  Acta Neurochir Suppl (Wien). 1997;  70 102-105
    Google Scholar
  • 170 Stein S C, Graham D I, Chen X H, Smith D H. Association between intravascular microthrombosis and cerebral ischemia in traumatic brain injury.  Neurosurgery. 2004;  54 (3) 687-691, discussion 691
    Google Scholar
  • 171 Kaufman H H, Hui K S, Mattson J C et al.. Clinicopathological correlations of disseminated intravascular coagulation in patients with head injury.  Neurosurgery. 1984;  15 (1) 34-42
    Google Scholar
  • 172 Kushimoto S, Yamamoto Y, Shibata Y, Sato H, Koido Y. Implications of excessive fibrinolysis and alpha(2)-plasmin inhibitor deficiency in patients with severe head injury.  Neurosurgery. 2001;  49 (5) 1084-1089, discussion 1089–1090
    Google Scholar
  • 173 Grenander A, Bredbacka S, Rydvall A et al.. Antithrombin treatment in patients with traumatic brain injury: a pilot study.  J Neurosurg Anesthesiol. 2001;  13 (1) 49-56
    Google Scholar
  • 174 Wahl F, Grosjean-Piot O, Bareyre F, Uzan A, Stutzmann J M. Enoxaparin reduces brain edema, cerebral lesions, and improves motor and cognitive impairments induced by a traumatic brain injury in rats.  J Neurotrauma. 2000;  17 (11) 1055-1065
    Google Scholar
  • 175 Dudley R R, Aziz I, Bonnici A et al.. Early venous thromboembolic event prophylaxis in traumatic brain injury with low-molecular-weight heparin: risks and benefits.  J Neurotrauma. 2010;  27 (12) 2165-2172
    Google Scholar
  • 176 Roos Y B, de Haan R J, Beenen L F, Groen R J, Albrecht K W, Vermeulen M. Complications and outcome in patients with aneurysmal subarachnoid haemorrhage: a prospective hospital based cohort study in the Netherlands.  J Neurol Neurosurg Psychiatry. 2000;  68 (3) 337-341
    Google Scholar
  • 177 Vergouwen M D, Vermeulen M, Coert B A, Stroes E S, Roos Y B. Microthrombosis after aneurysmal subarachnoid hemorrhage: an additional explanation for delayed cerebral ischemia.  J Cereb Blood Flow Metab. 2008;  28 (11) 1761-1770
    Google Scholar
  • 178 Romano J G, Forteza A M, Concha M et al.. Detection of microemboli by transcranial Doppler ultrasonography in aneurysmal subarachnoid hemorrhage.  Neurosurgery. 2002;  50 (5) 1026-1030, discussion 1030–1031
    Google Scholar
  • 179 Giller C A, Giller A M, Landreneau F. Detection of emboli after surgery for intracerebral aneurysms.  Neurosurgery. 1998;  42 (3) 490-493, discussion 493–494
    Google Scholar
  • 180 Crompton M R. The pathogenesis of cerebral infarction following the rupture of cerebral berry aneurysms.  Brain. 1964;  87 491-510
    Google Scholar
  • 181 Stein S C, Browne K D, Chen X H, Smith D H, Graham D I. Thromboembolism and delayed cerebral ischemia after subarachnoid hemorrhage: an autopsy study.  Neurosurgery. 2006;  59 (4) 781-787, discussion 787–788
    Google Scholar
  • 182 Wurm G, Tomancok B, Nussbaumer K, Adelwöhrer C, Holl K. Reduction of ischemic sequelae following spontaneous subarachnoid hemorrhage: a double-blind, randomized comparison of enoxaparin versus placebo.  Clin Neurol Neurosurg. 2004;  106 (2) 97-103
    Google Scholar
  • 183 Roos Y. STAR Study Group . Antifibrinolytic treatment in subarachnoid hemorrhage: a randomized placebo-controlled trial.  Neurology. 2000;  54 (1) 77-82
    Google Scholar
  • 184 Chwajol M, Starke R M, Kim G H, Mayer S A, Connolly E S. Antifibrinolytic therapy to prevent early rebleeding after subarachnoid hemorrhage.  Neurocrit Care. 2008;  8 (3) 418-426
    Google Scholar
  • 185 Starke R M, Kim G H, Fernandez A et al.. Impact of a protocol for acute antifibrinolytic therapy on aneurysm rebleeding after subarachnoid hemorrhage.  Stroke. 2008;  39 (9) 2617-2621
    Google Scholar
  • 186 Pabinger I, Karnik R, Lechner K, Slany J, Niessner H. Coumarin induced acral skin necrosis associated with hereditary protein C deficiency.  Blut. 1986;  52 (6) 365-370
    Google Scholar
  • 187 McGehee W G, Klotz T A, Epstein D J, Rapaport S I. Coumarin necrosis associated with hereditary protein C deficiency.  Ann Intern Med. 1984;  101 (1) 59-60
    Google Scholar
  • 188 Rose V L, Kwaan H C, Williamson K, Hoppensteadt D, Walenga J, Fareed J. Protein C antigen deficiency and warfarin necrosis.  Am J Clin Pathol. 1986;  86 (5) 653-655
    Google Scholar
  • 189 Sallah S, Abdallah J M, Gagnon G A. Recurrent warfarin-induced skin necrosis in kindreds with protein S deficiency.  Haemostasis. 1998;  28 (1) 25-30
    Google Scholar
  • 190 Dahlbäck B. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis.  Thromb Haemost. 1995;  74 (1) 139-148
    Google Scholar
  • 191 Kiehl R, Hellstern P, Wenzel E. Hereditary antithrombin III (AT III) deficiency and atypical localization of a coumarin necrosis.  Thromb Res. 1987;  45 (2) 191-193
    Google Scholar
  • 192 Fluri S, Kaczala G W, Leibundgut K, Alberio L. Chickenpox is not always benign: postvaricella purpura fulminans requires prompt and aggressive treatment.  Pediatr Emerg Care. 2010;  26 (12) 932-934
    Google Scholar
  • 193 Sharma V K, Dubey T N, Dave L, Agarwal A. Postvaricella purpura fulminans with no evidence of disseminated intravascular coagulation (DIC) or protein S deficiency.  J Indian Med Assoc. 2010;  108 (8) 529-530
    Google Scholar
  • 194 Francis Jr R B. Acquired purpura fulminans.  Semin Thromb Hemost. 1990;  16 (4) 310-325
    Google Scholar
  • 195 Josephson C, Nuss R, Jacobson L et al.. The varicella-autoantibody syndrome.  Pediatr Res. 2001;  50 (3) 345-352
    Google Scholar
  • 196 Manco-Johnson M J, Nuss R, Key N et al.. Lupus anticoagulant and protein S deficiency in children with postvaricella purpura fulminans or thrombosis.  J Pediatr. 1996;  128 (3) 319-323
    Google Scholar
  • 197 Busuttil D P, Hay C R, Lewis M A, Wynn R F. Aggressive multiple modality therapy for varicella-associated purpura fulminans.  Br J Haematol. 2000;  110 (4) 1012-1013
    Google Scholar

Hau C. KwaanM.D. Ph.D. 

Marjorie C. Barnett Professor of Hematology-Oncology, Professor of Medicine, Northwestern University Feinberg School of Medicine

710 Fairbanks Court, Olson Pavilion, Room 8258, Chicago, IL 60611

Email: h-kwaan@northwestern.edu

      >